Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines

Area of Science:

• Oncology
• Urology
• Clinical Practice Guidelines

Background:

• The National Comprehensive Cancer Network (NCCN) Guidelines provide essential clinical management recommendations for prostate cancer.
• Recent updates address evolving treatment paradigms and emerging therapies.

Purpose of the Study:

• To summarize key recent updates to the NCCN Clinical Practice Guidelines for Prostate Cancer.
• To highlight new recommendations and indications for prostate cancer therapies.

Main Methods:

• Review of recent NCCN Guidelines Insights for Prostate Cancer.
• Analysis of updated recommendations for hormonal agents, immunotherapy, and radiation therapy.

Main Results:

• Abiraterone acetate is a new standard of care for metastatic castration-recurrent prostate cancer after docetaxel (Category 1).
• Abiraterone acetate also has Category 2B recommendations for pre-chemotherapy settings.
• Sipuleucel-T is now an option for second-line therapy.
• Combination brachytherapy with external beam radiation therapy is an alternative for high-risk localized or locally advanced prostate cancer.

Conclusions:

• The NCCN Guidelines reflect advancements in prostate cancer treatment, offering new standards and options.
• These updates aim to optimize patient care through multidisciplinary recommendations.